I need to assess whether the substantive disclosure content meets the 150-word threshold. The filing contains financial statements, MD&A, and other substantive content referenced in the table of contents, but the actual extracted text cuts off before most of that content. However, the cover page, forward-looking statements section, and table of contents do contain substantive disclosure about the company's products, pipeline, and business activities that exceeds 150 words. Let me produce the article based on what is available in the filing text.

Vanda Pharmaceuticals Inc. filed its quarterly report on Form 10-Q with the SEC on October 29, 2026, covering the fiscal quarter ended September 30, 2026, and reporting 60,469,687 shares of common stock issued and outstanding as of October 22, 2026.

Key Highlights

  • Share count: As of October 22, 2026, the company had 60,469,687 shares of common stock issued and outstanding, according to the filing.
  • Filer status: Vanda Pharmaceuticals reported its status as an accelerated filer, not a large accelerated filer, smaller reporting company, or emerging growth company.
  • Commercial products: The filing identifies Fanapt (iloperidone), HETLIOZ (tasimelteon), PONVORY (ponesimod), NEREUS (tradipitant), BYSANTI (milsaperidone), and Quimilza (imsidolimab) as products in the company's portfolio or pipeline.
  • New product activity: The filing references NEREUS for the prevention of vomiting induced by motion, including through direct-to-consumer sales via the nereus.us website.
  • Pending FDA applications: The company disclosed efforts to obtain FDA approval for BYSANTI for major depressive disorder, NEREUS for prevention of vomiting induced by GLP-1 receptor agonists and for gastroparesis, and Quimilza for generalized pustular psoriasis.
  • Listing: The company's common stock trades on The Nasdaq Global Market under the symbol VNDA.

Vanda Pharmaceuticals Reports Q3 2026 Activities Across Expanding Product Portfolio

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), headquartered at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing was submitted under Commission File Number 001-34186. According to the cover page, the company confirmed that it had filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and had submitted all required Interactive Data Files electronically.

The filing describes a portfolio that, according to the company's own disclosures, includes several marketed and pipeline products. Fanapt (iloperidone) is disclosed as approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia. HETLIOZ (tasimelteon) is described as approved for Non-24-Hour Sleep-Wake Disorder and for nighttime sleep disturbances in Smith-Magenis syndrome, with the filing noting "existing and potential generic competition" as a factor affecting that product's U.S. sales. PONVORY (ponesimod) is identified as approved for adults with relapsing forms of multiple sclerosis. BYSANTI (milsaperidone) is described as being commercialized for bipolar I disorder and schizophrenia, with an FDA application pending for major depressive disorder.

The filing also identifies NEREUS (tradipitant) as a product for prevention of vomiting induced by motion, noting direct-to-consumer sales through the nereus.us website, and Quimilza (imsidolimab) as a candidate for which the company is seeking FDA approval for generalized pustular psoriasis. The company disclosed forward-looking statements regarding its commercial, regulatory, and research activities, cautioning that these are "subject to risks, changes in circumstances and uncertainties" and that actual results "may differ materially" from those expressed. These statements are the company's own and subject to its cautionary language as stated in the filing.

What Was Disclosed

Vanda Pharmaceuticals filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 60,469,687 shares outstanding as of October 22, 2026, its accelerated filer status, and its portfolio spanning marketed drugs and multiple pending FDA applications.